STERIS Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STERIS stock.
View analyst ratings for STERIS or view top-rated stocks.

Wall Street analysts have given STERIS a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but STERIS wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

STERIS is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for STERIS.

STERIS will be holding an earnings conference call on Tuesday, August 10th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "10158778".

STERIS plc (NYSE:STE) announced its earnings results on Tuesday, May, 18th. The medical equipment provider reported $1.63 EPS for the quarter, missing the consensus estimate of $1.80 by $0.17. The medical equipment provider earned $873.53 million during the quarter, compared to analysts' expectations of $874.38 million. STERIS had a trailing twelve-month return on equity of 14.17% and a net margin of 12.74%. The business's revenue for the quarter was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.64 earnings per share.
View STERIS's earnings history.

STERIS's stock was trading at $145.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, STE stock has increased by 50.7% and is now trading at $218.94.
View which stocks have been most impacted by COVID-19.

STERIS announced a quarterly dividend on Tuesday, May 18th. Stockholders of record on Friday, May 28th will be given a dividend of $0.40 per share on Friday, June 25th. This represents a $1.60 annualized dividend and a dividend yield of 0.73%. The ex-dividend date is Thursday, May 27th.
View STERIS's dividend history.

STERIS pays an annual dividend of $1.60 per share and currently has a dividend yield of 0.73%. STERIS has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of STERIS is 25.93%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STERIS will have a dividend payout ratio of 18.98% next year. This indicates that STERIS will be able to sustain or increase its dividend.
View STERIS's dividend history.

STERIS updated its FY 2022 earnings guidance on Tuesday, June, 15th. The company provided earnings per share guidance of $7.400-7.650 for the period, compared to the Thomson Reuters consensus estimate of $7.000. The company issued revenue guidance of $4.50 billion-4.50 billion, compared to the consensus revenue estimate of $3.74 billion.

5 brokers have issued 12 month target prices for STERIS's shares. Their forecasts range from $200.00 to $235.00. On average, they anticipate STERIS's stock price to reach $225.00 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price.
View analysts' price targets for STERIS or view top-rated stocks among Wall Street analysts.

196 employees have rated STERIS CEO Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among STERIS's employees.

Some companies that are related to STERIS include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), Hologic (HOLX), Insulet (PODD), Teleflex (TFX) and Masimo (MASI).
View all of STE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), The Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

STERIS's stock is owned by many different institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (1.63%), Fisher Asset Management LLC (0.61%), Villere ST Denis J & Co. LLC (0.50%), New York State Common Retirement Fund (0.47%), Boston Financial Mangement LLC (0.26%) and Boston Trust Walden Corp (0.25%). Company insiders that own STERIS stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Mohsen Sohi, Renato Tamaro, Richard C Breeden, Richard Martin Steeves and Walter M Rosebrough Jr.
View institutional ownership trends for STERIS.

STE stock was sold by a variety of institutional investors in the last quarter, including Clark Capital Management Group Inc., Fisher Asset Management LLC, PGGM Investments, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank , Copeland Capital Management LLC, Dupont Capital Management Corp, and Addenda Capital Inc.. Company insiders that have sold STERIS company stock in the last year include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Richard C Breeden, and Walter M Rosebrough Jr.
View insider buying and selling activity for STERIS or view top insider-selling stocks.

STE stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Asset Management One Co. Ltd., Victory Capital Management Inc., Waratah Capital Advisors Ltd., Boston Trust Walden Corp, Brinker Capital Investments LLC, State of Alaska Department of Revenue, and Foster Victor Wealth Advisors LLC.
View insider buying and selling activity for STERIS or or view top insider-buying stocks.

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STE stock can currently be purchased for approximately $218.94.

STERIS has a market capitalization of $18.69 billion and generates $3.11 billion in revenue each year. The medical equipment provider earns $397.40 million in net income (profit) each year or $6.17 on an earnings per share basis.

STERIS employs 13,000 workers across the globe.

STERIS was founded in 1987.

The official website for STERIS is www.steris.com.

STERIS is headquartered at 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296.

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at (531) 232-2000 or via email at [email protected]